At a meeting of the Reference Centre Directors it was agreed that for young children, and those who were newly diagnosed with haemophilia, cryoprecipitate was to be used. Next preference was to be given to NHS factor concentrate.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Professor Arthur L Bloom
Dr Charles Rizza